Last reviewed · How we verify
NCT06689228: Haemodialysis
The Effect of Education Based on Orem's Self-Care Deficit Theory and Tele-Monitoring on Rational Drug Use in Haemodialysis Patients
NA trial testing Rational Drug Use Training in Haemodialysis in 70 participants. Enrolling by invitation.
15 December 2024
Quick facts
| Lead sponsor | Akdeniz University |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 70 |
| Start date | 15 November 2024 |
| Primary completion | 15 December 2024 |
| Estimated completion | 15 January 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Rational Drug Use Training
Conditions studied
- Haemodialysis — all drugs for Haemodialysis →
Sponsor
Akdeniz University
Who can join
18 and older, any sex, with Haemodialysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with chronic kidney disease may show altered pharmacokinetic and pharmacodynamic response to many drugs compared to patients with normal renal function. Therefore, effective and safe drug use is difficult in patients with chronic kidney disease and especially in dialysis patients. In addition, some drugs may have nephrotoxic effects by causing further deterioration in renal function, especially in high-risk renal patients. Prevention of problems related to drug use in haemodialysis patients will be possible with rational drug use (RUD). RDM is defined as 'the set of rules to be followed in order for patients to take medicines in accordance with their clinical needs, in doses that meet their personal needs, in sufficient time, at the lowest cost to themselves and the society'. Rational drug use has become an increasingly important concept today. In studies investigating rational drug use, problems such as incorrect use of drugs, prescribing more drugs than necessary, unnecessary injection recommendation/administration, unnecessary antibiotic consumption, and unnecessary use of expensive drugs have been identified. As a result of incorrect drug use, poisoning or decreased sensitivity to drugs are observed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06689228
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Haemodialysis
Currently open trials in the same condition.
- NCT07427264 — The Effect of a Mixed-type Intradialytic Exercise Training Program on Body Composition, Functional Capacity, and Muscle · NA · active not recruiting
- NCT06641765 — Continuous Glucose Monitoring in Dialysis Patients With Diabetes · NA · active not recruiting
- NCT06225544 — Lumasiran in Hyperoxalaemic Patients on Haemodialysis · Phase 2 · recruiting
- NCT04842591 — Characteristics of Pulmonary Vascular Changes in Patients With Kidney Transplantation · active not recruiting
Other Akdeniz University trials
Trials by the same sponsor.
- NCT07581132 — Investigation of the Effect of Structured Energy Conservation Techniques Training on COPD Patients · NA · not yet recruiting
- NCT07469345 — Bruxism, Pelvic Pain, Erectile Dysfunction, and Anxiety in Young Adult Men · enrolling by invitation
- NCT07507279 — Technology-based Hand Rehabilitation in Older People · NA · not yet recruiting
- NCT07437924 — Bruxism and Pelvic Floor Dysfunction in Young Women · enrolling by invitation
- NCT07497308 — GDF-15 and Early Outcomes After LVAD Implantation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06689228 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Akdeniz University
- Last refreshed: 14 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06689228.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing